// App-Quantinova.ai

237 : Enrichment of AXL-high/ MITF-low melanoma cells in the presence of MAPK inhibitors in vitro

Researchers

Presenter

  • Ken Dutton-Regester

Principal Investigators

  • Levi Garraway

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

  • DMSO

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved